Published in Transplantation on October 15, 1997
HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood (2007) 1.00
Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation (1999) 0.96
History of clinical transplantation. World J Surg (2000) 0.91
Effect of HLA mismatch in African-Americans. Transplantation (1998) 0.77
Ushering in the era of penile transplantation. Transl Androl Urol (2017) 0.75
Simulation study of confounder-selection strategies. Am J Epidemiol (1993) 12.76
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA (1997) 9.54
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med (1995) 5.41
Racial equity in renal transplantation. The disparate impact of HLA-based allocation. JAMA (1993) 4.26
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
SEROTYPING FOR HOMOTRANSPLANTATION. VII. SELECTION OF KIDNEY DONORS FOR THIRTY-TWO RECIPIENTS. Ann N Y Acad Sci (1966) 2.25
The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation (1995) 2.13
Equitable allocation of HLA-compatible kidneys for local pools and minorities. N Engl J Med (1994) 2.12
Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med (1992) 2.09
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Analysis of HL-A incompatibility in human renal transplants. Tissue Antigens (1971) 1.89
Organ donation and blacks. A critical frontier. N Engl J Med (1991) 1.89
The point system for organ distribution. Transplant Proc (1989) 1.88
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood (1997) 1.65
Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow. Crucial role of histocompatiility matching. N Engl J Med (1969) 1.58
The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26
Cross-reactions to skin homografts in man. J Clin Invest (1962) 1.15
Living related and unrelated donors for kidney transplantation. A 28-year experience. Ann Surg (1995) 1.15
Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci U S A (1996) 1.14
Calculations on long-term graft and patient survival in human kidney transplantation. Transplant Proc (1977) 1.10
Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis (1993) 1.05
CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995. Southeastern Organ Procurement Foundation. Clin Transplant (1996) 0.99
Antigen-independent determinants of cadaveric kidney transplant failure. JAMA (1996) 0.99
Risk rate and long-term kidney transplant survival. Clin Transpl (1996) 0.98
Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol (1994) 0.96
The politics of grafting cadaver kidneys. Lancet (1996) 0.95
Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol (1987) 0.94
Nephron mass modulates the hemodynamic, cellular, and molecular response of the rat renal allograft. Transplantation (1997) 0.90
Nomenclature for factors of the HLA System, 1996. Hum Immunol (1997) 0.86
The graft survival curve: ideology and rhetoric. Transplant Proc (1992) 0.85
The impact of nonidentical ABO cadaveric renal transplantation on waiting times and graft survival. Am J Kidney Dis (1991) 0.80
Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation (1990) 0.80
HLA matching should be utilized for improving kidney transplant success rates. Transplant Proc (1991) 0.80
A ten-year prediction for kidney transplant survival. Clin Transpl (1992) 0.80
HLA matching: a comparison of conventional and molecular approaches. Clin Transpl (1992) 0.77
HLA matching effect: better survival rates and graft quality. Clin Transpl (1994) 0.77
Cadaveric kidney allocation in the United States: a critical analysis of the point system. Transplant Proc (1995) 0.77
The effect of HLA-A, -B matching on cadaver renal allograft rejection comparing public and private specificities. Transplantation (1984) 0.76
Recipient pool sizes for prioritized HLA matching. Transplantation (1989) 0.76
Multifactorial analysis of renal transplants reported to the United Network for Organ Sharing Registry: a 1994 update. Clin Transpl (1994) 0.76
Behavior of HLA-compatible and incompatible skin allografts in human recipients preimmunized with pooled leukocyte extracts obtained from randomly selected donors. Transplantation (1983) 0.76
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med (1991) 18.33
The impact of patient-centered care on outcomes. J Fam Pract (2000) 15.07
A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med (2001) 13.85
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (1998) 11.27
High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med (1973) 9.90
Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol (1981) 9.21
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation (1968) 8.51
Kidney transplantation under FK 506. JAMA (1990) 7.45
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
The portal circulation: I. The action of adrenaline and pituitary pressor extract. J Physiol (1932) 6.88
Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88
WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. Lancet (2001) 6.86
Sample size and optimal designs for reliability studies. Stat Med (1998) 6.80
Small sample performance of tests of homogeneity of odds ratios in K 2 x 2 tables. Stat Med (1992) 6.20
Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet (2004) 5.93
Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet (2003) 5.90
Evaluation of a palliative care service: problems and pitfalls. BMJ (1994) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Autologous stimulation of human lymphocyte subpopulation. J Exp Med (1975) 4.80
The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med (2000) 4.67
Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44
Cytotoxins in disease. Autocytotoxins in lupus. N Engl J Med (1970) 4.40
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Serotyping for homotransplantation. X. Survival of 196 grafted kidneys subsequent to typing. Transplantation (1967) 4.16
Developments in cluster randomized trials and Statistics in Medicine. Stat Med (2007) 4.12
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Kidney preservation for transportation. Initial perfusion and 30 hours' ice storage. Lancet (1969) 3.67
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Effect of blood transfusions on subsequent kidney transplants. Transplant Proc (1973) 3.42
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients. Stroke (1999) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Approaches to sample size estimation in the design of clinical trials--a review. Stat Med (1984) 3.28
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Sample size requirements for reliability studies. Stat Med (1987) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Analysis of data arising from a stratified design with the cluster as unit of randomization. Stat Med (1987) 3.01
Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00
Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Do the facts and figures warrant a 10-fold increase in the performance of carotid endarterectomy on asymptomatic patients? Neurology (1996) 2.89
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Non-alcoholic duct destructive chronic pancreatitis. Gut (1997) 2.79
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Detection of Y chromosome sequences in Turner's syndrome by Southern blot analysis of amplified DNA. Lancet (1993) 2.65
Medical education and health for all. Aust J Public Health (1995) 2.65
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
CARDIAC CATHETERIZATION IN CASES OF PATENT INTERAURICULAR SEPTUM, PRIMARY PULMONARY HYPERTENSION, FALLOT'S TETRALOGY, AND PULMONARY STENOSIS. Br Heart J (1947) 2.57
Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA (2000) 2.56
Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med (1978) 2.52
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
The portal circulation: II. The action of acetylcholine. J Physiol (1933) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Transplantation of kidneys from donors whose hearts have stopped beating. N Engl J Med (1998) 2.48
Methods in health service research. Evaluation of health interventions at area and organisation level. BMJ (1999) 2.48
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45
Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med (1990) 2.40
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet (1979) 2.33
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29